Drug Search Results
More Filters [+]

Tefibazumab

Alternative Names: tefibazumab
Latest Update: 2013-03-29
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tefibazumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Cystic Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

INH-AUR-004

P2

Completed

Cystic Fibrosis

None

Recent News Events

Date

Type

Title